RecruitingPhase 2NCT07172386

Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC

A Study on the Safety and Efficacy of Super-selective Tumour Arterial Embolisation in Combination With Toripalimab and Axitinib as a Preoperative Treatment for Advanced Renal Cell Carcinoma

Sponsor

Tianjin Medical University Second Hospital

Enrollment

40 participants

Start Date

Jul 31, 2025

Study Type

INTERVENTIONAL

Conditions

Renal Cell Carcinoma (RCC)

Summary

This is a phase II study to determine the efficacy and safety of Super-selective tumor artery embolization combined with toripalimab and axitinib as treatment for patients with the advanced kidney cancer . Further evaluate whether the treatment plan is beneficial to the patient's operation. Patients will undergo super-selective embolization of the feeding arteries to the renal tumour one week prior to drug therapy, followed by toripalimab administered every three weeks for three to four consecutive cycles combined with axitinib administered for four consecutive cycles in the preoperative and patients need to continue taking the drug for a year after surgery

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying a combination approach before kidney cancer surgery: blocking the tumor's blood supply (super-selective embolization) plus two cancer drugs (toripalimab, an immunotherapy, and axitinib, a targeted therapy). The goal is to shrink the tumor before surgery and improve surgical outcomes. **You may be eligible if...** - You are 18 or older with confirmed advanced kidney cancer (renal cell carcinoma) that meets specific staging criteria - Your cancer is operable (can be surgically removed or reduced) - You are in good physical condition (ECOG 0–1) - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You have brain metastases - Your cancer has spread extensively and cannot be brought back to a resectable stage - You have active autoimmune disease or serious prior immune-related side effects - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGToripalimab and axitinib

Patients will undergo super-selective embolization of the feeding arteries to the renal tumour one week prior to drug therapy, followed by toripalimab administered every three weeks for four consecutive cycles combined with axitinib administered for four consecutive cycles before surgery, and followed by 17 cycles' toripalimab for adjuvant therapy.